Avidity's Losses Widen Amid Soaring R&D, Novartis Merger Looms

Avidity Biosciences, Inc. 10-Q Filing Summary
FieldDetail
CompanyAvidity Biosciences, Inc.
Form Type10-Q
Filed DateNov 10, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentmixed

Sentiment: mixed

Topics: Biotechnology, RNA Therapeutics, Mergers and Acquisitions, Pharmaceuticals, R&D Spending, Net Loss, Liquidity

Related Tickers: RNA, NVS

TL;DR

**Avidity's burning cash on R&D, but the Novartis acquisition is a lifeline, making this a clear exit play for shareholders.**

AI Summary

Avidity Biosciences, Inc. reported a significant increase in collaboration revenue for the nine months ended September 30, 2025, reaching $17.895 million, up from $7.924 million in the prior year, representing a 125.8% increase. However, the company's net loss widened substantially to $447.530 million for the nine months ended September 30, 2025, compared to a net loss of $220.045 million for the same period in 2024. This increased loss was driven by a sharp rise in operating expenses, with research and development (R&D) expenses more than doubling to $392.563 million from $207.968 million, and general and administrative (G&A) expenses increasing to $116.797 million from $57.902 million. The company maintains a strong liquidity position with $350.158 million in cash and cash equivalents and $1.525 billion in marketable securities as of September 30, 2025. A key strategic development is the Merger Agreement with Novartis AG and the related Separation and Distribution Agreement, both entered into on October 25, 2025, which will result in Avidity becoming an indirect wholly owned subsidiary of Novartis and the spin-off of certain early-stage precision cardiology programs to Bryce Therapeutics, Inc. The company expects to continue incurring net losses as it advances its product candidates and development programs, and plans to finance future needs through equity offerings, debt, or collaborations.

Why It Matters

This filing reveals Avidity's significant R&D investment, which is crucial for a biopharmaceutical company developing a new class of RNA therapeutics. The substantial increase in net loss, despite rising collaboration revenue, highlights the high-risk, high-reward nature of drug development. For investors, the impending merger with Novartis AG, announced post-quarter, is a game-changer, potentially offering a premium and integration into a larger pharmaceutical powerhouse, while the spin-off of early-stage assets to Bryce Therapeutics, Inc. could create a new investment opportunity. This strategic move could reshape the competitive landscape in RNA therapeutics, impacting rivals and potentially accelerating the development of Avidity's AOC platform.

Risk Assessment

Risk Level: medium — The company's accumulated deficit reached $1.340 billion as of September 30, 2025, and it continues to incur substantial net losses, with a net loss of $447.530 million for the nine months ended September 30, 2025. While the company has a strong cash position of $350.158 million in cash and cash equivalents and $1.525 billion in marketable securities, the significant cash burn from R&D expenses ($392.563 million for the nine months) indicates ongoing operational risk, though the Novartis merger mitigates immediate liquidity concerns.

Analyst Insight

Investors should hold Avidity Biosciences (RNA) shares, anticipating the successful completion of the merger with Novartis AG, which is expected to provide a favorable exit. Those interested in early-stage precision cardiology programs should monitor the spin-off of Bryce Therapeutics, Inc. for potential future investment opportunities.

Financial Highlights

revenue
$17.895M
total Assets
$2.134B
total Debt
$0.248B
net Income
$-447.530M
eps
$-3.38
cash Position
$1.876B
revenue Growth
+125.8%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration Revenue$17.895M+125.8%

Key Numbers

  • $17.895M — Collaboration Revenue (Increased from $7.924M in 2024 for the nine months ended September 30, 2025)
  • $447.530M — Net Loss (Widened from $220.045M in 2024 for the nine months ended September 30, 2025)
  • $392.563M — Research and Development Expenses (Increased from $207.968M in 2024 for the nine months ended September 30, 2025)
  • $116.797M — General and Administrative Expenses (Increased from $57.902M in 2024 for the nine months ended September 30, 2025)
  • $1.340B — Accumulated Deficit (As of September 30, 2025)
  • $350.158M — Cash and Cash Equivalents (As of September 30, 2025)
  • $1.525B — Marketable Securities (As of September 30, 2025)
  • 150,675,742 — Common Stock Outstanding (As of October 31, 2025)
  • $837.420M — Proceeds from Public Offerings (Net of issuance costs for the nine months ended September 30, 2025)
  • $480.668M — Net Cash Used in Operating Activities (For the nine months ended September 30, 2025)

Key Players & Entities

  • Avidity Biosciences, Inc. (company) — registrant and biopharmaceutical company
  • Novartis AG (company) — acquiring parent company in merger agreement
  • Ajax Acquisition Sub, Inc. (company) — Merger Sub, indirect wholly owned subsidiary of Novartis AG
  • Bryce Therapeutics, Inc. (company) — newly formed Delaware corporation for spin-off assets
  • SEC (regulator) — Securities and Exchange Commission
  • FASB (regulator) — Financial Accounting Standards Board
  • The Nasdaq Global Market (company) — exchange where common stock is registered
  • Avidity Biosciences Ireland Limited (company) — wholly-owned subsidiary

FAQ

What were Avidity Biosciences' key financial results for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Avidity Biosciences reported collaboration revenue of $17.895 million, a significant increase from $7.924 million in the prior year. However, the company's net loss widened to $447.530 million, compared to a net loss of $220.045 million for the same period in 2024.

How did Avidity Biosciences' operating expenses change in the latest quarter?

Avidity Biosciences' operating expenses increased substantially. Research and development expenses rose to $392.563 million for the nine months ended September 30, 2025, from $207.968 million in the prior year. General and administrative expenses also increased to $116.797 million from $57.902 million over the same period.

What is the strategic outlook for Avidity Biosciences following the 10-Q filing?

The strategic outlook for Avidity Biosciences is dominated by the Agreement and Plan of Merger with Novartis AG, entered into on October 25, 2025. This merger will result in Avidity becoming an indirect wholly owned subsidiary of Novartis, while certain early-stage precision cardiology programs will be spun off into Bryce Therapeutics, Inc.

What is Avidity Biosciences' current liquidity position?

As of September 30, 2025, Avidity Biosciences maintained a strong liquidity position with $350.158 million in cash and cash equivalents and $1.525 billion in marketable securities. The company believes these existing funds will be sufficient to fund operations for at least 12 months from the filing date.

What are the primary risks highlighted in Avidity Biosciences' 10-Q?

The primary risks include a limited operating history, continued incurrence of net losses, and the need for future funding through equity offerings, debt financings, or collaborations. The accumulated deficit of $1.340 billion as of September 30, 2025, underscores the financial challenges, although the Novartis merger significantly de-risks the company's future.

How many shares of common stock did Avidity Biosciences have outstanding?

As of October 31, 2025, Avidity Biosciences had 150,675,742 shares of common stock outstanding. This figure reflects issuances from public offerings, stock option exercises, and vesting of restricted stock units.

What is an AOC platform, and why is it important for Avidity Biosciences?

An AOC (Antibody Oligonucleotide Conjugate) platform is Avidity Biosciences' proprietary technology designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics. This platform is crucial as it aims to target the root cause of diseases previously untreatable with such therapeutics, representing a new class of RNA therapeutics.

What accounting pronouncements is Avidity Biosciences currently evaluating?

Avidity Biosciences is currently evaluating the impact of ASU 2023-09 (Income Taxes: Improvements to Income Tax Disclosures), ASU 2024-03 (Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures), and ASU 2025-06 (Intangibles - Goodwill and Other - Internal-Use Software) on its financial statements.

What was the net cash used in operating activities for Avidity Biosciences?

For the nine months ended September 30, 2025, Avidity Biosciences reported net cash used in operating activities of $480.668 million. This represents a significant increase from the $200.999 million used in operating activities during the same period in 2024.

What is the significance of the Separation and Distribution Agreement for Avidity Biosciences?

The Separation and Distribution Agreement, dated October 25, 2025, is significant because it outlines a pre-closing reorganization of certain assets related to Avidity's early-stage precision cardiology programs and collaboration agreements. These assets will be transferred to Bryce Therapeutics, Inc., a newly formed wholly-owned subsidiary, in connection with the Novartis merger.

Risk Factors

  • Sustained Net Losses and Need for Future Funding [high — financial]: The company reported a net loss of $447.530 million for the nine months ended September 30, 2025, a substantial increase from $220.045 million in the prior year. This trend is expected to continue as R&D expenses more than doubled to $392.563 million. Future funding will likely rely on equity offerings, debt, or collaborations, introducing financial risk.
  • Intensified Research and Development Spending [high — operational]: R&D expenses surged to $392.563 million for the nine months ended September 30, 2025, from $207.968 million in the prior year. This significant increase reflects the company's aggressive advancement of its product candidates and development programs, posing operational challenges and requiring substantial resource allocation.
  • Merger with Novartis and Spin-off [medium — regulatory]: The pending merger with Novartis AG and the spin-off of early-stage programs to Bryce Therapeutics, Inc. introduce significant integration and regulatory complexities. Changes in corporate structure and strategic direction could impact ongoing development and market access.
  • Accumulated Deficit Growth [high — financial]: The accumulated deficit grew to $1.340 billion as of September 30, 2025. This substantial deficit highlights the company's history of operating at a loss and underscores the need for successful future product development and commercialization to achieve profitability.
  • Increased General and Administrative Expenses [medium — operational]: G&A expenses rose to $116.797 million for the nine months ended September 30, 2025, from $57.902 million in the prior year. This increase may reflect scaling operations, increased compliance requirements, or costs associated with strategic transactions.

Industry Context

Avidity Biosciences operates in the highly competitive biotechnology sector, focusing on RNA therapeutics. The industry is characterized by rapid innovation, significant R&D investment, and a high rate of clinical trial failures. Success often hinges on securing strategic partnerships and navigating complex regulatory pathways.

Regulatory Implications

The pending merger with Novartis and the spin-off of assets introduce significant regulatory considerations related to antitrust approvals, securities filings, and the transfer of intellectual property. Compliance with evolving FDA and international regulatory standards for novel RNA therapeutics remains critical.

What Investors Should Do

  1. Monitor the progress and terms of the Novartis merger and Bryce Therapeutics spin-off.
  2. Evaluate the sustainability of R&D spending relative to pipeline progress.
  3. Assess the company's cash runway and future financing needs.

Key Dates

  • 2025-10-25: Merger Agreement and Separation and Distribution Agreement with Novartis AG — Marks a significant strategic shift, with Avidity becoming a subsidiary of Novartis and certain assets being spun off, impacting future operations and shareholder value.

Glossary

Collaboration Revenue
Revenue generated from partnerships and agreements with other companies, often involving milestone payments or shared development costs. (A key growth driver for Avidity, indicating successful partnerships.)
Accumulated Deficit
The total cumulative net losses of a company since its inception, less any cumulative net income. (Indicates the company's historical profitability and ongoing investment in growth.)
Marketable Securities
Investments in financial instruments that can be readily bought or sold in the open market. (Represents a significant portion of Avidity's liquid assets, providing financial flexibility.)
Right-of-use assets
Assets representing a lessee's right to use an identified asset for a period of time, typically related to leases. (Reflects the company's leasing of facilities or equipment, impacting its asset base and liabilities.)

Year-Over-Year Comparison

Avidity Biosciences has demonstrated substantial revenue growth, with collaboration revenue increasing by 125.8% to $17.895 million for the nine months ended September 30, 2025. However, this growth has been accompanied by a significant widening of the net loss to $447.530 million, driven by a more than doubling of R&D expenses to $392.563 million and a substantial increase in G&A expenses. The company's cash and marketable securities position remains strong, but the increased operating expenses and accumulated deficit highlight ongoing financial challenges.

Filing Stats: 4,608 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2025-11-10 16:12:54

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value RNA The Nasdaq Global Market

Filing Documents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38

SIGNATURES

SIGNATURES 40 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) Avidity Biosciences, Inc. Condensed Consolidated Balance Sheets (in thousands, except par value) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 350,158 $ 219,868 Marketable securities 1,525,678 1,281,629 Prepaid and other current assets 90,181 40,793 Total current assets 1,966,017 1,542,290 Property and equipment, net 21,504 12,670 Restricted cash 2,798 2,795 Right-of-use assets 52,848 5,619 Other assets 91,042 521 Total assets $ 2,134,209 $ 1,563,895 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 9,626 $ 8,461 Accrued expenses and other liabilities 137,163 64,726 Lease liabilities, current portion 3,967 3,844 Deferred revenue, current portion 19,123 20,987 Total current liabilities 169,879 98,018 Lease liabilities, net of current portion 45,999 2,957 Deferred revenue, net of current portion 32,066 37,961 Total liabilities 247,944 138,936 Commitments and contingencies (Note 7) Stockholders' equity: Common stock, $ 0.0001 par value; authorized shares – 400,000 ; issued and outstanding shares – 146,771 and 119,893 at September 30, 2025 and December 31, 2024, respectively 15 12 Additional paid-in capital 3,225,078 2,315,111 Accumulated other comprehensive income 1,768 2,902 Accumulated deficit ( 1,340,596 ) ( 893,066 ) Total stockholders' equity 1,886,265 1,424,959 Total liabilities and stockholders' equity $ 2,134,209 $ 1,563,895 See accompanying notes. 3 Table of Contents Avidity Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Collaboration revenue $ 12,475 $ 2,336 $ 17,895 $ 7,924 Operating expenses: Research and development 154,948 77,197 392,563 207,968 General and administrative 46,333 23,273

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.